Hematology/Oncology

Top Story

University of Alabama at Birmingham appoints cancer center director

University of Alabama at Birmingham appoints cancer center director
June 24, 2017

Michael J. Birrer, MD, PhD, has been named director of University of Alabama at Birmingham Comprehensive Cancer Center.

Birrer’s appointment will be effective Aug. 1. He will succeed Edward E. Partridge, MD, who will retire from University of Alabama at Birmingham (UAB) after a 48-year career.

Meeting NewsVideo

VIDEO: Questions remain regarding use of gene-targeted therapy for lung cancer

June 23, 2017
CHICAGO — Suresh S. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, discusses the results of a phase 3 trial that demonstrated…

10 updates in immunotherapy research

June 23, 2017
In recognition of Cancer Immunotherapy Month, Cancer Research Institute has organized a series of educational and social events designed to raise awareness regarding…
FDA News

FDA approves BevyxXa for prevention of venous thromboembolism

June 23, 2017
The FDA granted approval to betrixaban for the prevention of venous thromboembolism and pulmonary embolism in acutely ill patients who are not undergoing surgery…
In the Journals Plus

Midostaurin extends survival in acute myeloid leukemia with FLT3 mutation

June 23, 2017
The addition of midostaurin to standard chemotherapy improved OS and EFS among patients with acute myeloid leukemia and FLT3 mutation, according to results of the RATIFY…
More News Headlines »
CME

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately…
More »
Video
Meeting News

VIDEO: Adam Brufsky, MD, PhD, discusses results of MONARCH-2, PALOMA-1 trials

June 23, 2017
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement